CY1124369T1 - Συνθεση εμφυτευματος ρισπεριδονης ή/και παλιπεριδονης - Google Patents
Συνθεση εμφυτευματος ρισπεριδονης ή/και παλιπεριδονηςInfo
- Publication number
- CY1124369T1 CY1124369T1 CY20211100644T CY211100644T CY1124369T1 CY 1124369 T1 CY1124369 T1 CY 1124369T1 CY 20211100644 T CY20211100644 T CY 20211100644T CY 211100644 T CY211100644 T CY 211100644T CY 1124369 T1 CY1124369 T1 CY 1124369T1
- Authority
- CY
- Cyprus
- Prior art keywords
- paliperidone
- risperidone
- weeks
- glycolic acid
- lactic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε μια ενέσιμη σύνθεση μακράς διάρκειας δράσης (depot) για ενδομυϊκή χορήγηση, κατάλληλη για τον in situ σχηματισμό στερεού εμφυτεύματος εντός του οργανισμού, αποτελούμενη από τα φάρμακα ρισπεριδόνη ή/και παλιπεριδόνη ή οποιοδήποτε από τα φαρμακευτικώς αποδεκτά άλατα τους σε οποιονδήποτε συνδυασμό, ένα βιοσυμβατό συμπολυμερές βασισμένο σε γαλακτικό και γλυκολικό οξύ με αναλογία μονομερών γαλακτικού οξέος προς γλυκολικό οξύ 50:50 περίπου, και DMSO ως διαλύτη μιας σύνθεσης η οποία αποδεσμεύει το φάρμακο με άμεση έναρξη της δράσης και συνεχώς επί 4 εβδομάδες τουλάχιστον, με in vivo φαρμακοκινητικό προφίλ που την καθιστά κατάλληλη για χορήγηση κάθε 4 εβδομάδες ή ακόμη και ανά μεγαλύτερα χρονικά διαστήματα.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2011/059001 WO2011151356A2 (en) | 2010-05-31 | 2011-05-31 | Methods for the preparation of injectable depot compositions |
| PCT/EP2011/059000 WO2011151355A1 (en) | 2010-05-31 | 2011-05-31 | Antipsychotic injectable depot composition |
| EP12170362.3A EP2529756B1 (en) | 2011-05-31 | 2012-05-31 | Risperidone and/or Paliperidone implant formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124369T1 true CY1124369T1 (el) | 2022-07-22 |
Family
ID=46147376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100644T CY1124369T1 (el) | 2011-05-31 | 2021-07-16 | Συνθεση εμφυτευματος ρισπεριδονης ή/και παλιπεριδονης |
Country Status (30)
| Country | Link |
|---|---|
| EP (2) | EP2529756B1 (el) |
| JP (1) | JP6367795B2 (el) |
| KR (1) | KR101880716B1 (el) |
| CN (1) | CN104363923A (el) |
| AU (1) | AU2013269547B2 (el) |
| BR (1) | BR112014029209A2 (el) |
| CA (1) | CA2874765C (el) |
| CL (1) | CL2014003216A1 (el) |
| CO (1) | CO7160108A2 (el) |
| CY (1) | CY1124369T1 (el) |
| DK (1) | DK2529756T3 (el) |
| EA (1) | EA031819B1 (el) |
| ES (1) | ES2878112T3 (el) |
| HR (1) | HRP20211057T1 (el) |
| IL (1) | IL235849B (el) |
| IN (1) | IN2014DN10672A (el) |
| LT (1) | LT2529756T (el) |
| MA (1) | MA37664B1 (el) |
| MX (1) | MX2014014483A (el) |
| MY (1) | MY174999A (el) |
| NZ (1) | NZ703321A (el) |
| PH (1) | PH12014502667B1 (el) |
| PL (1) | PL2529756T3 (el) |
| PT (1) | PT2529756T (el) |
| RS (1) | RS62059B1 (el) |
| SG (1) | SG11201407961WA (el) |
| SI (1) | SI2529756T1 (el) |
| UA (1) | UA119430C2 (el) |
| WO (1) | WO2013178812A1 (el) |
| ZA (1) | ZA201409299B (el) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| JP2010531807A (ja) | 2007-05-25 | 2010-09-30 | トルマー セラピューティクス， インコーポレイテッド | リスペリドン化合物の徐放送達製剤 |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| ES2589106T3 (es) | 2010-05-31 | 2016-11-10 | Laboratorios Farmaceuticos Rovi, S.A. | Composición inyectable antipsicótica de liberación controlada |
| US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
| US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| LT2394663T (lt) | 2010-05-31 | 2022-02-10 | Laboratorios Farmaceuticos Rovi, S.A. | Kompozicijos, skirtos įšvirkščiamiems in situ biologiškai skaidiems implantams |
| PT2529756T (pt) * | 2011-05-31 | 2021-07-28 | Farm Rovi Lab Sa | Formulação de implante de risperidona e/ou paliperidona |
| ES2456917T3 (es) * | 2011-05-31 | 2014-04-24 | Laboratorios Farmacéuticos Rovi, S.A. | Formulación de implante de paliperidona |
| US9737605B2 (en) | 2013-03-11 | 2017-08-22 | Durect Corporation | Injectable controlled release composition comprising high viscosity liquid carrier |
| US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
| CN104922085B (zh) * | 2015-06-01 | 2016-10-26 | 湖南赛沃药业有限公司 | 一种利培酮植入剂及其制备方法 |
| CN109589304A (zh) * | 2017-10-01 | 2019-04-09 | 万特制药(海南)有限公司 | 利培酮口服溶液及其制备方法 |
| EP3801462A4 (en) | 2018-05-24 | 2022-03-16 | Celanese EVA Performance Polymers LLC | IMPLANTABLE DEVICE FOR EXTENDED RELEASE OF A MACROMOLECULAR DRUG COMPOUND |
| KR20210013089A (ko) | 2018-05-24 | 2021-02-03 | 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 | 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치 |
| TW202313047A (zh) | 2021-09-21 | 2023-04-01 | 西班牙商禾霏藥品實驗室有限公司 | 抗精神病可注射儲積型組合物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK282231B6 (sk) | 1993-11-19 | 2001-12-03 | Janssen Pharmaceutica N. V. | Farmaceutický prostriedok na liečenie psychotických porúch |
| US7658998B2 (en) * | 2003-01-22 | 2010-02-09 | Alkermes Controlled Therapeutics, Inc. | Method of preparing sustained release microparticles |
| EP1660039B1 (en) * | 2003-07-18 | 2016-09-28 | Oakwood Laboratories L.L.C. | Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| KR101340946B1 (ko) | 2004-08-04 | 2013-12-13 | 알자 코포레이션 | 오름차 0차 방출 패턴을 나타내는 약물의 서방성 조성물,상기 조성물을 제조하는 방법 |
| JP5315336B2 (ja) | 2007-04-19 | 2013-10-16 | 又欣 李 | 精神疾患治療用の新規化合物とその調剤及び使用 |
| CA2686137C (en) * | 2007-05-18 | 2021-01-12 | Durect Corporation | Improved depot formulations |
| JP2010531807A (ja) * | 2007-05-25 | 2010-09-30 | トルマー セラピューティクス， インコーポレイテッド | リスペリドン化合物の徐放送達製剤 |
| US20090036470A1 (en) | 2007-07-27 | 2009-02-05 | Jiri Bartl | Paliperidone derivatives |
| EP2234617B1 (en) | 2007-12-19 | 2021-03-31 | Janssen Pharmaceutica NV | Dosing regimen associated with long acting injectable paliperidone esters |
| WO2011042453A1 (en) | 2009-10-06 | 2011-04-14 | Ascendis Pharma As | Subcutaneous paliperidone composition |
| ES2589106T3 (es) * | 2010-05-31 | 2016-11-10 | Laboratorios Farmaceuticos Rovi, S.A. | Composición inyectable antipsicótica de liberación controlada |
| LT2394663T (lt) * | 2010-05-31 | 2022-02-10 | Laboratorios Farmaceuticos Rovi, S.A. | Kompozicijos, skirtos įšvirkščiamiems in situ biologiškai skaidiems implantams |
| PT2529756T (pt) * | 2011-05-31 | 2021-07-28 | Farm Rovi Lab Sa | Formulação de implante de risperidona e/ou paliperidona |
| ES2456917T3 (es) * | 2011-05-31 | 2014-04-24 | Laboratorios Farmacéuticos Rovi, S.A. | Formulación de implante de paliperidona |
-
2012
- 2012-05-31 PT PT121703623T patent/PT2529756T/pt unknown
- 2012-05-31 RS RS20210834A patent/RS62059B1/sr unknown
- 2012-05-31 EP EP12170362.3A patent/EP2529756B1/en active Active
- 2012-05-31 LT LTEP12170362.3T patent/LT2529756T/lt unknown
- 2012-05-31 PL PL12170362T patent/PL2529756T3/pl unknown
- 2012-05-31 DK DK12170362.3T patent/DK2529756T3/da active
- 2012-05-31 SI SI201231933T patent/SI2529756T1/sl unknown
- 2012-05-31 ES ES12170362T patent/ES2878112T3/es active Active
-
2013
- 2013-05-31 AU AU2013269547A patent/AU2013269547B2/en active Active
- 2013-05-31 EP EP13726003.0A patent/EP2854858A1/en active Pending
- 2013-05-31 WO PCT/EP2013/061320 patent/WO2013178812A1/en active Application Filing
- 2013-05-31 JP JP2015514533A patent/JP6367795B2/ja active Active
- 2013-05-31 EA EA201401346A patent/EA031819B1/ru unknown
- 2013-05-31 MY MYPI2014703551A patent/MY174999A/en unknown
- 2013-05-31 MX MX2014014483A patent/MX2014014483A/es active IP Right Grant
- 2013-05-31 CA CA2874765A patent/CA2874765C/en active Active
- 2013-05-31 CN CN201380027927.8A patent/CN104363923A/zh active Pending
- 2013-05-31 NZ NZ703321A patent/NZ703321A/en unknown
- 2013-05-31 KR KR1020147035300A patent/KR101880716B1/ko active IP Right Grant
- 2013-05-31 SG SG11201407961WA patent/SG11201407961WA/en unknown
- 2013-05-31 UA UAA201414187A patent/UA119430C2/uk unknown
- 2013-05-31 BR BR112014029209A patent/BR112014029209A2/pt not_active Application Discontinuation
- 2013-05-31 IN IN10672DEN2014 patent/IN2014DN10672A/en unknown
-
2014
- 2014-11-23 IL IL235849A patent/IL235849B/en active IP Right Grant
- 2014-11-26 CL CL2014003216A patent/CL2014003216A1/es unknown
- 2014-11-28 PH PH12014502667A patent/PH12014502667B1/en unknown
- 2014-12-16 MA MA37664A patent/MA37664B1/fr unknown
- 2014-12-17 ZA ZA2014/09299A patent/ZA201409299B/en unknown
- 2014-12-30 CO CO14285844A patent/CO7160108A2/es unknown
-
2021
- 2021-07-02 HR HRP20211057TT patent/HRP20211057T1/hr unknown
- 2021-07-16 CY CY20211100644T patent/CY1124369T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124369T1 (el) | Συνθεση εμφυτευματος ρισπεριδονης ή/και παλιπεριδονης | |
| EA201401348A1 (ru) | Технология приготовления имплантируемой формы палиперидона | |
| CY1123370T1 (el) | Σταθερη ενεσιμη φαρμακευτικη συνθεση ανταγωνιστη υποδοχεα νευροκινινης 1 και μεθοδος παρασκευης αυτης | |
| CY1120975T1 (el) | Συστημα αποθεματος που περιλαμβανει οξικη γλατιραμερη | |
| CY1122771T1 (el) | Φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης για τη χορηγηση πρωτεϊνων στον οφθαλμο και μεθοδοι για την παρασκευη αυτων | |
| CY1122624T1 (el) | Θεραπεια συνδυασμου του καρκινου | |
| RS53205B (en) | IMPLANTABLE PALIPERIDON FORMULATION | |
| CY1120005T1 (el) | Συνεχης χορηγηση αναστολεων l-ντοπα, αποκαρβοξυλασης ντοπα, αναστολεων κατεχολ-ο-μεθυλ τρανσφερασης και συνθεσεις αυτων | |
| CY1118183T1 (el) | Φαρμακευτικη μορφη δοσης η οποια περιεχει νιφεδιπινη ή νισολδιπινη και εναν ανταγωνιστη αγγειοτενσινης ιι ή/και ενα διουρητικο | |
| CY1124037T1 (el) | Παρασκευη φορτωμενων με πεπτιδιο μικροσφαιριδιων plga me χαρακτηριστικα ελεγχομενης απελευθερωσης | |
| AR088250A1 (es) | Forma de dosificacion farmaceutica oral resistente a alteracion comprendiendo agonista opioide y antagonista opioide | |
| CY1118057T1 (el) | Φαρμακευτικη συνθεση για στοματικη χορηγηση | |
| UA108885C2 (uk) | Композиція рисперидону для ін'єкційної депо-форми | |
| CY1124782T1 (el) | Φαρμακοτεχνικες μορφες μακρας δρασης | |
| MX2022003939A (es) | Composicion farmaceutica de estabilidad mejorada. | |
| MX2020008471A (es) | Formulaciones inyectables de larga duracion y formas de cristal de derivados de buprenorfina. | |
| MY195509A (en) | Pharmaceutical Formulations for Sustained Release of Sebacoyl Dinalbuphine Ester | |
| CY1119701T1 (el) | Σταθερη φαρμακευτικη συνθεση που περιεχει υδροχλωρικη βαρδεναφιλη | |
| CY1120749T1 (el) | Φαρμακευτικες δοσολογικες μορφες |